# US iPS Cell Derived Organoids Market

> US IPS Cell-Derived Organoids Market Research Report By Type (Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids, Others), By Application (Drug Discovery and Development, Disease Modelling, Regenerative Medicine) and By End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organization) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.2%
- **2024:** $ 142.8 Million
- **2025:** $ 150.23 Million
- **2035:** $ 249.5 Million
- **Key Players:** Organovo Holdings Inc (US), Stemcell Technologies Inc (CA), Cellectis SA (FR), Fate Therapeutics Inc (US), Asterias Biotherapeutics Inc (US), Regenative Labs LLC (US), TissUse GmbH (DE), InSphero AG (CH)

**Report ID:** MRFR/LS/52344-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-ips-cell-derived-organoids-market-54106

---

## Market Summary

## **US IPS  Cell-Derived Organoids Market Overview**

As per MRFR analysis, the US IPS  Cell-Derived Organoids Market Size was estimated at 123.2 (USD Million) in 2023. The US IPS  Cell-Derived Organoids Market Industry is expected to grow from 142.8(USD Million) in 2024 to 865.08 (USD Million) by 2035. The US IPS  Cell-Derived Organoids Market CAGR (growth rate) is expected to be around 17.793% during the forecast period (2025 - 2035)

**Key US IPS  Cell-Derived Organoids Market Trends Highlighted**

The US IPS  cell-derived organoids market is experiencing significant growth driven by advancements in cell culture technologies and increased funding from government bodies and private organizations for regenerative medicine research. This expansion is fueled by the growing interest in personalized medicine, as organoids derived from patient-specific IPS  cells offer tailored approaches for drug testing and disease modeling. The high prevalence of chronic diseases in the US also drives the demand for innovative therapies and treatments, leveraging the unique properties of organoids for better patient outcomes.

Additionally, collaborations between academic institutions and biopharmaceutical companies are enhancing research capabilities, making it easier to translate lab discoveries into therapeutic applications. Opportunities abound in the US market as the regulatory landscape evolves to support the safe introduction of organoid-based therapies. The National Institutes of Health (NIH) and the Food and Drug Administration (FDA) have been actively engaged in creating frameworks that facilitate research while ensuring safety and ethical considerations.

There’s room for growth in areas such as organoid-based tissue engineering and the development of disease-specific organoids for conditions like cancer, infectious diseases, and neurodegenerative disorders.  In recent times, the trend towards high-throughput screening and automation in laboratories has gained momentum. This allows for quicker and more efficient experimentation with organoids, which can lead to faster drug discovery processes. The integration of artificial intelligence and machine learning with organoid technology is also emerging, optimizing the analysis of complex biological systems and providing deeper insights into disease mechanisms.

This confluence of technology and biology is pivotal for the US IPS  cell-derived organoids market, setting the stage for future innovations.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**US IPS  Cell-Derived Organoids Market Drivers**

**Increasing Investment in Stem Cell Research**

One of the factors propelling the US IPS  Cell-Derived Organoids Market Industry is the substantial investment being made in stem cell research in the US. The National Institutes of Health reports that throughout the last five years, funding for stem cell research has increased by around 30%, leading to previously unheard-of breakthroughs in cell and organoid technology. The market for induced pluripotent stem (IPS ) cells is expected to increase significantly as a result of several new studies and applications, which are being supported by institutions such as the National Science Foundation.

The demand for IPS  cell-derived organoids is anticipated to rise quickly as researchers continue to investigate new possibilities for organoid applications in drug testing and disease modeling. This will increase the market's overall value and promote partnershIPS  between US biotech companies and academic institutions.

**Rising Prevalence of Genetic Disorders**

The increase in genetic disorders across the US population is a significant factor propelling the growth of the US IPS  Cell-Derived Organoids Market Industry. Reports from the Centers for Disease Control and Prevention indicate that approximately 1 in 33 babies is born with a genetic disorder each year, highlighting the urgent need for effective research and therapeutic options. With institutions such as the American Society of Human Genetics advocating for further study into genetic variations, IPS  cell-derived organoids present an innovative solution for studying these disorders.

As more genetic data becomes resourced for research, the versatility of organoids in modeling these complex diseases is likely to expand, thereby increasing the market demand for IPS  cell-derived organoids.

**Advancements in Personalized Medicine**

The growing emphasis on personalized medicine within the healthcare system is another catalyst for the US IPS  Cell-Derived Organoids Market Industry. The American Medical Association has reported a 20% increase in the adoption of personalized treatment approaches among healthcare providers in the last three years. IPS  cell-derived organoids offer researchers the opportunity to create patient-specific models to tailor therapies uniquely suited to individual genetic profiles. By leveraging large biobanks of human samples and the integration of artificial intelligence in data analysis, institutions are developing highly targeted therapies that could significantly improve treatment outcomes.

This surge in personalized medicine initiatives is not only transforming patient care but also paving the way for a surge in the utilization of IPS  cell-derived organoids across various research applications.

**US IPS  Cell-Derived Organoids Market Segment Insights**

**IPS  Cell-Derived Organoids Market Type Insights  **

The US IPS  Cell-Derived Organoids Market is gaining traction due to the advancements in stem cell research and its significant potential in regenerative medicine. The 'Type' segmentation includes categories such as Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids, and Others, each contributing uniquely to the overall growth and application of organoid technologies. Brain Organoids are pivotal for understanding complex neurological conditions and drug discovery, providing a platform for studying neurodevelopment and neurodegeneration.

Heart Organoids play a crucial role in cardiovascular research, particularly in modeling diseases and testing therapeutics, addressing the high prevalence of heart diseases in the US population. Lung Organoids are significant in respiratory disease modeling and drug testing, especially in the context of the increasing incidence of conditions such as asthma and chronic obstructive pulmonary disease (COPD) in the US. Liver Organoids serve as a model for understanding metabolic diseases and liver toxicity, presenting opportunities for personalized medicine approaches in hepatology. Kidney Organoids are essential for studying renal diseases, offering insights into the mechanisms of kidney injury and regeneration.

The 'Others' category reflects additional diverse organoid applications, showcasing the versatility and adaptability of IPS  cell-derived technologies across various research fields. Each type plays a crucial role in translational medicine, enhancing our understanding of human diseases and paving the way for innovative treatments, which is integral to the growth trajectory of the US IPS  Cell-Derived Organoids Market. The increasing investment in Research and Development (R&D) and collaborations between academic institutions and industry players further bolsters the potential of these organoid types, indicating a promising outlook for the future.

The market is also driven by a growing demand for more accurate preclinical models that can better mimic human organ systems, ultimately reducing the failure rates in clinical trials. As the US continues to prioritize advancements in healthcare technology, the IPS  Cell-Derived Organoids Market is positioned to expand significantly, supported by its diverse applications and the need for innovative solutions in personalized medicine.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**IPS  Cell-Derived Organoids Market Application Insights  **

The Application segment of the US IPS  Cell-Derived Organoids Market plays a crucial role in advancing medical research and therapeutic development. Within this segment, Drug Discovery and Development is pivotal as it enhances the efficiency of pharmaceutical testing by providing more accurate models that mimic human biology. This leads to a significant reduction in the time and cost of bringing new drugs to market. Disease Modelling is another important area, allowing researchers to study the cellular mechanisms of various diseases with greater precision.

By utilizing IPS  cell-derived organoids, scientists have been able to gain insights into disease progression and potential treatment pathways that are more reflective of in vivo conditions. Furthermore, Regenerative Medicine is a key focus, as organoids derived from IPS  cells hold the promise of developing personalized therapies that can repair or replace damaged tissues. This multifaceted approach within the Application segment underscores its significance in driving innovation and improving outcomes in health care, highlighting the importance of IPS  Cell-Derived Organoids in shaping future medical solutions.

The overall dynamics of the market are also influenced by increasing investments in Research and Development, collaborative efforts between academia and industry, and a growing demand for personalized medicine in the US.

**IPS  Cell-Derived Organoids Market End User Insights  **

The End User segment of the US IPS  Cell-Derived Organoids Market plays a critical role in advancing scientific research and drug development. Pharmaceutical and Biotechnology Companies are increasingly utilizing IPS  cell-derived organoids for their potential in personalized medicine, as these models closely mimic human physiology, aiding in drug response studies and toxicity testing. Academic and Research Institutes are essential as they drive fundamental research, facilitating breakthroughs in regenerative medicine and disease modeling. Meanwhile, Contract Research Organizations support both pharmaceutical and academic sectors by providing specialized services for drug discovery and development, thereby streamlining processes and reducing time to market.

The emphasis on innovative technologies in these areas reflects the growing importance of organoid research in understanding complex biological systems. Collectively, these segments significantly contribute to the US IPS  Cell-Derived Organoids Market by enhancing the efficiency and efficacy of biomedical research, ultimately leading to improved therapeutic outcomes.

**US IPS  Cell-Derived Organoids Market Key Players and Competitive Insights**

The US IPS  Cell-Derived Organoids Market is characterized by dynamic innovations and advancements that play a crucial role in various biomedical applications, including drug discovery, disease modeling, and personalized medicine. With an increasing demand for personalized therapeutic solutions and advancements in stem cell research technologies, the competitive landscape is marked by numerous players vying for market share. Companies are focusing on collaborations, mergers, and strategic partnershIPS  to enhance their product offerings and improve research capabilities.

Continuous investment in research and development is evident, leading to innovative solutions that promise to shape the future of regenerative medicine and organoid technologies in the US. Horizon Discovery stands out in the US IPS  Cell-Derived Organoids Market with its strong focus on genetic engineering and gene editing capabilities. The company leverages its proprietary technologies to provide advanced organoid models that meet the growing needs of researchers in various sectors, including academia and pharmaceuticals. A key strength of Horizon Discovery is its extensive repository of CRISPR-modified cell lines, which significantly contributes to the versatility and efficacy of their organoid models.

The company’s commitment to quality and innovation allows it to maintain a competitive edge in this burgeoning market. Furthermore, Horizon Discovery has strategically aligned its operations within the US by enhancing its collaborations with research institutions, thereby solidifying its presence in the local market and further driving advancements in organoid research. Stemcell Technologies is a prominent player in the US IPS  Cell-Derived Organoids Market, known for its comprehensive range of cell culture products designed to support the growth and maintenance of organoids.

The company’s key offerings, such as specialized media and reagents tailored for the cultivation of IPS -derived organoids, have positioned it favorably among researchers and biotech firms. Stemcell Technologies boasts a strong market presence in the US, with its products widely adopted in leading academic and research institutions. 

A significant strength lies in the company’s commitment to research collaboration and customer support, which enhances user experience and fosters loyalty. Additionally, Stemcell Technologies is actively engaged in mergers and acquisitions to expand its product portfolio and deepen its market penetration, allowing it to remain ahead of competitors in the US IPS  Cell-Derived Organoids Market. The combination of innovative product offerings and strategic growth initiatives contributes to the company's robust positioning and continued success in this rapidly evolving sector.

**Key Companies in the US IPS  Cell-Derived Organoids Market Include**

- Horizon Discovery
- Stemcell Technologies
- CureMetrix
- Organogenesis
- Tissue Regeneration
- Aeonian Therapeutics
- Q BIOGEN
- NantWorks
- Thermo Fisher Scientific
- Corning
- Celerion
- InSphero
- Charles River Laboratories
- 1CellBio
- Kiyatec

**US IPS  Cell-Derived Organoids Market Industry Developments**

Recent developments in the US IPS  Cell-Derived Organoids Market showcase a significant trajectory of growth and innovation among key players such as Horizon Discovery and Stemcell Technologies, which have been advancing their organoid culture techniques and applications in drug discovery and disease modeling. In July 2023, CureMetrix announced a strategic partnership with Organogenesis to enhance the development of predictive diagnostics, leveraging tissue regeneration techniques. Furthermore, Aeonian Therapeutics secured new funding to establish better methodologies for organoid production, signaling confidence in the market's potential. 

A noteworthy merger was documented in April 2023 when Thermo Fisher Scientific acquired Celerion to strengthen its position in biomarker and organoid research, reflecting a broader strategy to integrate capabilities in the biopharmaceutical sector. The market valuation of companies like Corning and InSphero continues to rise, largely due to an increased focus on personalized medicine and regenerative therapies. Over the past two to three years, initiatives in the US have focused on accelerating research, with significant federal funding aimed at advancing organoid technologies and their applications, further fueled by collaborations among leading industry players.

**IPS  Cell-Derived Organoids Market Segmentation Insights**

**IPS Cell-Derived Organoids Market Type Outlook**

- Brain Organoids
- Heart Organoids
- Lung Organoids
- Liver Organoids
- Kidney Organoids
- Others

**IPS Cell-Derived Organoids Market Application Outlook**

- Drug Discovery and Development
- Disease Modelling
- Regenerative Medicine

**IPS Cell-Derived Organoids Market End User Outlook**

- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Contract Research Organization

## Market Drivers

### Growing Interest in Drug Discovery

The increasing focus on drug discovery is a pivotal driver for the iPSC-derived organoids market. Pharmaceutical companies are actively seeking innovative methods to enhance drug development processes. Organoids derived from induced pluripotent stem cells (iPSCs) offer a more accurate representation of human tissues, which can lead to improved drug efficacy and safety profiles. The market for drug discovery is projected to reach approximately $50 billion by 2026, indicating a robust growth trajectory. This trend suggests that the integration of iPSC-derived organoids into drug discovery pipelines could significantly streamline the process, thereby attracting substantial investments and interest from biopharmaceutical firms. As a result, the demand for organoids is likely to surge, further propelling the growth of the ips cell-derived-organoids market.

### Rising Prevalence of Chronic Diseases

The escalating prevalence of chronic diseases in the United States is a significant driver for the ips cell-derived-organoids market. Conditions such as cancer, diabetes, and neurodegenerative disorders are on the rise, necessitating advanced research and therapeutic strategies. iPSC-derived organoids provide a unique platform for studying disease mechanisms and testing potential treatments in a more relevant biological context. The market for chronic disease management is expected to exceed $1 trillion by 2025, highlighting the urgent need for innovative solutions. This growing demand for effective therapies is likely to propel the adoption of organoids in research and clinical applications, thereby enhancing the prospects of the ips cell-derived-organoids market.

### Regulatory Support for Stem Cell Research

Regulatory frameworks in the United States are increasingly supportive of stem cell research, which is a crucial driver for the ips cell-derived-organoids market. Agencies such as the FDA have established guidelines that facilitate the use of iPSCs in research and therapeutic applications. This regulatory backing not only enhances the credibility of iPSC-derived organoids but also encourages researchers and companies to invest in this technology. The National Institutes of Health (NIH) has allocated significant funding towards stem cell research, amounting to over $1 billion annually. Such financial support, combined with favorable regulations, is likely to stimulate innovation and development within the ips cell-derived-organoids market, fostering a conducive environment for growth.

### Collaboration Between Academia and Industry

The increasing collaboration between academic institutions and industry players is a notable driver for the ips cell-derived-organoids market. Universities and research organizations are partnering with biotechnology and pharmaceutical companies to leverage their expertise in iPSC technology. These collaborations often lead to the development of novel organoid models that can be utilized for drug testing and disease modeling. Such partnerships are becoming more common, with funding for collaborative research projects reaching approximately $2 billion annually in the U.S. This synergy not only accelerates innovation but also enhances the commercial viability of iPSC-derived organoids, thereby contributing to the growth of the ips cell-derived-organoids market.

### Technological Advancements in Organoid Culture

Technological advancements in organoid culture techniques are driving the growth of the ips cell-derived-organoids market. Innovations in 3D bioprinting, microfluidics, and biomaterials are enabling the development of more sophisticated organoid models that closely mimic in vivo conditions. These advancements enhance the reproducibility and scalability of organoid production, making them more accessible for research and therapeutic applications. The market for 3D bioprinting alone is projected to reach $6 billion by 2027, indicating a strong trend towards integrating advanced technologies in organoid research. As these technologies continue to evolve, they are likely to further propel the adoption of iPSC-derived organoids, thereby fostering growth in the ips cell-derived-organoids market.

## Future Outlook

The [IPS Cell Derived Organoids Market](https://www.marketresearchfuture.com/reports/ips-cell-derived-organoids-market-28623) is projected to grow at a 5.2% CAGR from 2025 to 2035, driven by advancements in regenerative medicine, personalized therapies, and increased R&D investments.

**New opportunities:**

- Development of custom organoid models for pharmaceutical testing.
- Partnerships with biotech firms for innovative therapeutic applications.
- Expansion into educational platforms for organoid research training.

By 2035, the market is expected to achieve substantial growth, reflecting its critical role in biomedical research.

## Segment Insights

### By Type: Brain Organoids (Largest) vs. Lung Organoids (Fastest-Growing)

The market share distribution among the different types of organoids reveals that brain organoids hold the largest segment, driven by their applications in neurological research and drug development. Heart organoids follow, with specific use cases in cardiovascular studies, while lung, liver, and kidney organoids also capture significant portions of the market, reflecting their varied research applications in organ function and disease modeling.

Growth trends indicate that lung organoids are emerging as the fastest-growing segment, propelled by increasing interest in respiratory diseases and advancements in regenerative medicine. Additionally, the continued investment in biomedical research and novel therapeutic strategies for complex diseases further boosts the demand for organoids in various studies, enhancing their roles in personalized medicine and disease modeling.

Brain Organoids (Dominant) vs. Lung Organoids (Emerging)

Brain organoids represent a dominant force in the US ips cell-derived-organoids market, primarily due to their critical role in studying neurological disorders, brain development, and drug efficacy. Their complex cellular architecture mimics in vivo conditions, allowing researchers to explore neural networks and disease mechanisms more effectively. In contrast, lung organoids are emerging as a dynamic segment, especially as research focuses on respiratory conditions and the potential for developing personalized therapies. Their ability to model lung pathology and response to therapies uniquely positions them in the evolving landscape of organoid applications, highlighting a shift towards targeted and patient-specific approaches in research and clinical settings.

### By Application: Drug Discovery (Largest) vs. Regenerative Medicine (Fastest-Growing)

The US ips cell-derived-organoids market exhibits distinct applications, with Drug Discovery dominating the landscape due to its pivotal role in therapeutic advancements. This segment significantly outpaces the others, capturing the attention of major pharmaceutical firms focused on innovative treatment modalities. Disease Modelling follows, serving as a critical bridge between preclinical studies and actual patient treatment, whereas Regenerative Medicine is gaining traction, being increasingly recognized for its potential to revolutionize treatment methodologies in various health conditions.

Growth trends in this segment are driven by a surge in research funding and technological advancements facilitating complex disease modelling. Drug Discovery is witnessing accelerating investments as firms look to streamline their pipelines and improve outcomes, while Regenerative Medicine's innovative approaches promise transformative therapies, thereby appealing to an increasing number of biotech ventures. As regulatory frameworks evolve and acceptance grows, these applications are poised for remarkable expansion in the coming years.

Drug Discovery (Dominant) vs. Regenerative Medicine (Emerging)

Drug Discovery is characterized by its integral role in advancing pharmaceutical development, utilizing ips cell-derived-organoids to model human biology effectively. This segment not only enhances drug efficacy predictions but also diminishes the time and cost associated with traditional drug development processes. In contrast, Regenerative Medicine is emerging as a game-changing field, leveraging the unique properties of ips cell-derived-organoids to foster tissue regeneration and repair. Researchers are progressively exploring this domain for treatments of chronic diseases and injury recovery, highlighting its potential to offer novel therapeutic solutions. As both segments progress, their interplay will likely drive innovations and enhance patient outcomes.

### By End User: Pharmaceutical and Biotechnology Companies (Largest) vs. Academic and Research Institutes (Fastest-Growing)

The US ips cell-derived-organoids market is primarily driven by the strong presence of Pharmaceutical and Biotechnology Companies, which dominate the market share, contributing significantly to research and drug development efforts. These companies utilize organoids for therapeutic innovations and personalized medicine, thus solidifying their position as the largest end-user segment. In contrast, Academic and Research Institutes are experiencing faster growth as they increasingly adopt advanced technologies for research purposes and collaborations, focusing on breakthroughs in disease modeling and regenerative medicine.

The growth trends in the US ips cell-derived-organoids market indicate a robust expansion fueled by rising investments in stem cell research, increasing demand for personalized therapies, and technological advancements in organoid creation. Pharmaceutical and Biotechnology Companies are leveraging organoids to streamline drug discovery and improve the efficiency of clinical trials. Meanwhile, Academic and Research Institutes are rapidly adopting these technologies, driven by governmental and private funding aimed at advancing medical research and fostering innovations in therapeutic applications.

Pharmaceutical and Biotechnology Companies (Dominant) vs. Academic and Research Institutes (Emerging)

Pharmaceutical and Biotechnology Companies represent the dominant force within the US ips cell-derived-organoids market, focusing on innovative solutions in drug discovery and personalized medicine. These organizations possess substantial resources, enabling them to implement cutting-edge technologies and establish partnerships for research and development. On the other hand, Academic and Research Institutes are emerging as a crucial segment due to escalating interest in stem cell research and collaborative studies. They currently emphasize knowledge generation and practical applications of organoids, such as disease modeling and drug testing, which are instrumental for advancing healthcare solutions. The blend of these segments illustrates a dynamic market landscape where established players and emerging institutions collectively contribute to significant advancements in organoid technology.

### By Source of Induced Pluripotent Stem Cells: Adult Somatic Cells (Largest) vs. Fibroblasts (Fastest-Growing)

In the US iPS cell-derived organoids market, the source of induced pluripotent stem cells displays a varied landscape. Adult somatic cells emerge as the largest segment, widely adopted for their adaptability in organoid applications and recognized for their high efficiency in reprogramming. Meanwhile, fibroblasts have quickly gained traction, showcasing a significant increase in usage driven by their availability and ease of procurement, making them an appealing choice for researchers and biotechnologists alike.
As the market evolves, several growth trends are shaping the sources of iPS cells. The increasing focus on personalized medicine and regenerative therapies is fueling demand for induced pluripotent stem cell technologies. Additionally, advancements in reprogramming techniques and regulatory support are encouraging researchers to explore diverse cellular sources, paving the way for innovations and the commercialization of new organoid-based applications.

Adult Somatic Cells (Dominant) vs. Cord Blood Cells (Emerging)

Adult somatic cells are considered the dominant player in the US iPS cell-derived organoids market, primarily due to their established protocols for reprogramming and the wide range of organoid applications they support. They allow for efficient generation of patient-specific organoids, which are crucial for drug testing and disease modeling. In contrast, cord blood cells are emerging as a promising alternative source, valued for their ethical collection methods and rich regenerative potential. Researchers are increasingly discovering the benefits of cord blood-derived iPS cells, which may offer unique advantages in specific therapeutic contexts, thereby widening their appeal and use in future medical research and therapeutic applications. The shift towards more ethical sourcing may further enhance their position in the market.

## Competitive Benchmarking

The [ips cell-derived-organoids market](https://www.marketresearchfuture.com/reports/ips-cell-derived-organoids-market-28623) is currently characterized by a dynamic competitive landscape, driven by advancements in regenerative medicine and personalized therapies. Key players such as Organovo Holdings Inc (US), Fate Therapeutics Inc (US), and Stemcell Technologies Inc (CA) are at the forefront, each adopting distinct strategies to enhance their market positioning. Organovo Holdings Inc (US) focuses on innovation in bioprinting technologies, aiming to create complex tissue structures that can be utilized for drug testing and disease modeling. Meanwhile, Fate Therapeutics Inc (US) emphasizes the development of cell-based immunotherapies, leveraging its proprietary induced pluripotent stem cell (iPSC) technology to create off-the-shelf therapies. Stemcell Technologies Inc (CA) is strategically positioned as a supplier of tools and services for stem cell research, which supports a broad range of applications in the organoid space. Collectively, these strategies contribute to a competitive environment that is increasingly focused on technological advancement and therapeutic efficacy.
In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several players vying for market share while also collaborating on research initiatives. This fragmentation allows for a diverse range of products and services, catering to various segments within the ips cell-derived-organoids market. The collective influence of these key players is shaping a landscape where innovation and strategic partnerships are paramount.
In October 2025, Fate Therapeutics Inc (US) announced a collaboration with a leading pharmaceutical company to develop novel iPSC-derived organoid models for drug discovery. This partnership is likely to enhance their research capabilities and expand their product offerings, positioning them favorably in the competitive landscape. The strategic importance of this collaboration lies in its potential to accelerate the development of new therapies, thereby addressing unmet medical needs in oncology and other therapeutic areas.
In September 2025, Organovo Holdings Inc (US) unveiled a new bioprinting platform designed to create more complex organoid structures. This technological advancement is expected to significantly improve the accuracy of drug testing and disease modeling, which could lead to better patient outcomes. The introduction of this platform underscores the company's commitment to innovation and its strategic focus on enhancing the utility of organoids in research and therapeutic applications.
In August 2025, Stemcell Technologies Inc (CA) launched a new line of products specifically tailored for the cultivation of organoids from iPSCs. This move not only broadens their product portfolio but also reinforces their position as a key supplier in the market. The strategic significance of this launch lies in its potential to facilitate more efficient research processes, thereby attracting a wider customer base and fostering collaborations with academic and research institutions.
As of November 2025, current competitive trends in the ips cell-derived-organoids market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) in research processes. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve, with a shift from price-based competition to a focus on technological advancements, innovative solutions, and reliable supply chains. This transition may ultimately redefine how companies compete, emphasizing the importance of research and development in maintaining a competitive edge.

## Recent News & Developments

Recent developments in the US IPS  Cell-Derived Organoids Market showcase a significant trajectory of growth and innovation among key players such as Horizon Discovery and Stemcell Technologies, which have been advancing their organoid culture techniques and applications in drug discovery and disease modeling. In July 2023, CureMetrix announced a strategic partnership with Organogenesis to enhance the development of predictive diagnostics, leveraging tissue regeneration techniques. Furthermore, Aeonian Therapeutics secured new funding to establish better methodologies for organoid production, signaling confidence in the market's potential. 

A noteworthy merger was documented in April 2023 when Thermo Fisher Scientific acquired Celerion to strengthen its position in biomarker and organoid research, reflecting a broader strategy to integrate capabilities in the biopharmaceutical sector. The market valuation of companies like Corning and InSphero continues to rise, largely due to an increased focus on personalized medicine and regenerative therapies. Over the past two to three years, initiatives in the US have focused on accelerating research, with significant federal funding aimed at advancing organoid technologies and their applications, further fueled by collaborations among leading industry players.

## Report Scope

| MARKET SIZE 2024 | 142.8(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 150.23(USD Million) |
| MARKET SIZE 2035 | 249.5(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.2% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Organovo Holdings Inc (US), Stemcell Technologies Inc (CA), Cellectis SA (FR), Fate Therapeutics Inc (US), Asterias Biotherapeutics Inc (US), Regenative Labs LLC (US), TissUse GmbH (DE), InSphero AG (CH) |
| Segments Covered | Type, Application, End User |
| Key Market Opportunities | Advancements in personalized medicine drive demand for innovative applications in the ips cell-derived-organoids market. |
| Key Market Dynamics | Rising demand for personalized medicine drives innovation and competition in the ips cell-derived-organoids market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current market valuation of the US ips cell-derived-organoids market?**
A: The market valuation was $142.8 Million in 2024.

**Q: What is the projected market size for the US ips cell-derived-organoids market by 2035?**
A: The projected market size is $249.5 Million by 2035.

**Q: What is the expected CAGR for the US ips cell-derived-organoids market during the forecast period 2025 - 2035?**
A: The expected CAGR is 5.2% during the forecast period 2025 - 2035.

**Q: Which segments are included in the US ips cell-derived-organoids market?**
A: The segments include Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids, and Others.

**Q: What was the market value for Brain Organoids in 2024?**
A: The market value for Brain Organoids was $28.56 Million in 2024.

**Q: How much is the Drug Discovery and Development segment projected to grow by 2035?**
A: The Drug Discovery and Development segment is projected to grow from $60.0 Million to $105.0 Million by 2035.

**Q: Who are the key players in the US ips cell-derived-organoids market?**
A: Key players include Organovo Holdings Inc, Stemcell Technologies Inc, Cellectis SA, Fate Therapeutics Inc, Asterias Biotherapeutics Inc, Regenative Labs LLC, TissUse GmbH, and InSphero AG.

**Q: What is the market value for Liver Organoids in 2024?**
A: The market value for Liver Organoids was $14.28 Million in 2024.

**Q: Which end users are involved in the US ips cell-derived-organoids market?**
A: End users include Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Contract Research Organizations.

**Q: What is the projected market value for Kidney Organoids by 2035?**
A: The projected market value for Kidney Organoids is expected to reach $26.83 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-ips-cell-derived-organoids-market-54106*